文献速递皮肤肿瘤

Hedgehog通路抑制剂治疗局部晚期基底细胞癌的疗效与耐受性比较:免疫治疗新时代的专家意见

Comparison of efficacy and tolerability of hedgehog pathway inhibitors for locally advanced basal cell carcinoma: An expert opinion in the new age of immunotherapy.
PubMed 文献 · J Am Acad Dermatol · 2026-10-08

本文为叙述性综述,基于关键临床试验(ERIVANCE、BOLT、STEVIE、MIKIE)、FDA标签及真实世界数据,比较vismodegib与sonidegib治疗局部晚期或转移性基底细胞癌的疗效、不良反应、药代动力学和耐药机制。专家意见认为sonidegib中位缓解持续时间更长、疾病控制更持久,延迟起效的不良反应和更深组织穿透利于浸润性或高风险疾病;vismodegib处方更广但不良反应起效更早,因半衰期较短而治疗中断更具挑战。两者仍是晚期基底细胞癌的重要治疗工具,理解其药理学和临床差异有助于个体化治疗。

要点

  • sonidegib中位缓解持续时间更长、疾病控制更持久,延迟起效不良反应和更深组织穿透利于浸润性或高风险疾病。
  • vismodegib处方更广但不良反应起效更早,半衰期较短使治疗中断更具挑战。
  • 调整剂量和不良反应缓解策略及新辅助应用可改善两药耐受性和结局。

核心结论

  • sonidegib较vismodegib中位缓解持续时间更长、疾病控制更持久,延迟起效不良反应和更深组织穿透利于浸润性或高风险疾病。
  • vismodegib处方更广但不良反应起效更早,半衰期较短使治疗中断更具挑战。
  • 两药仍是晚期基底细胞癌的重要治疗工具,理解药理学和临床差异有助于个体化治疗并拓展新辅助和维持治疗应用。

研究设计与样本

  • 叙述性综述,分析关键临床试验(ERIVANCE、BOLT、STEVIE、MIKIE)、FDA标签和真实世界数据。

主要发现

  • sonidegib中位缓解持续时间更长、疾病控制更持久。
  • sonidegib不良反应延迟起效且组织穿透更深,利于浸润性或高风险疾病。
  • vismodegib不良反应起效更早,半衰期较短使治疗中断更具挑战。

临床怎么用

  • 根据药理学和临床差异个体化选择SMO抑制剂,浸润性或高风险疾病可优先考虑sonidegib。
  • 采用调整剂量和不良反应缓解策略改善两药耐受性。
  • 可探索SMO抑制剂的新辅助和维持治疗应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Basal cell carcinoma (BCC) is the most diagnosed malignancy. While most cases are curable, a subset progresses to unresectable locally advanced (laBCC) or metastatic BCC (mBCC). The Smoothened inhibitors (SMOi) vismodegib and sonidegib have significantly improved outcomes in these cases. However, differences in trial design, pharmacokinetics, adverse effects (AEs), and real-world application warrant clinical comparison. This narrative review examines key clinical trials (ERIVANCE, BOLT, STEVIE, MIKIE), FDA labeling, and real-world data. Efficacy outcomes, AE profiles, pharmacokinetics, and resistance mechanisms are analyzed alongside expert recommendations for optimizing treatment. In expert opinion, sonidegib demonstrates a longer median duration of response and more durable disease control compared to vismodegib. Its delayed-onset AEs and deeper tissue penetration make it favorable for infiltrative or high-risk disease. Vismodegib, though more widely prescribed, is associated with earlier-onset AEs and challenges with treatment interruptions due to its shorter half-life. Tailored dosing and AE mitigation strategies as well as neoadjuvant applications of SMOi improve tolerability and outcomes for both agents. Both vismodegib and sonidegib remain essential tools in the management of advanced BCC. Understanding their pharmacologic and clinical differences enables more personalized treatment planning, enhancing long-term outcomes and expanding their use in neoadjuvant and maintenance settings.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Millan SH, Sun KH, Tan M, et al. Comparison of efficacy and tolerability of hedgehog pathway inhibitors for locally advanced basal cell carcinoma: An expert opinion in the new age of immunotherapy. J Am Acad Dermatol. 2026. PMID: 42849742. doi:10.1016/j.jaad.2026.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。